5 citations
,
January 2022 in “Dermatology Reports” Tofacitinib treatment for hair loss may worsen acne.
10 citations
,
August 2024 in “Chemical Engineering Journal” The ATAN-Met hydrogel helps heal infected diabetic wounds by promoting tissue regeneration and fighting bacteria.
June 2018 in “Surgical Case Reports” S-1 treatment led to a complete response in pancreatic cancer with manageable side effects.
9 citations
,
April 2025 in “International Journal of Nanomedicine” An injectable ibuprofen gel speeds up diabetic wound healing by reducing inflammation and promoting tissue growth.
May 2018 in “Dermatologic Surgery” June 2021 in “DOAJ (DOAJ: Directory of Open Access Journals)” JAK inhibitors show promise for treating alopecia areata but their effectiveness and safety are still debated.
July 2023 in “Journal of the ASEAN Federation of Endocrine Societies” Metyrapone effectively stabilizes severe Cushing's disease symptoms before surgery.
May 2012 in “Journal of Clinical Oncology” Taking 5-alpha reductase inhibitors might be linked to breast cancer in men.
37 citations
,
October 2017 in “Clinical and Experimental Dermatology” Oral tofacitinib shows promise in treating atopic dermatitis and alopecia areata, but only slight improvement in vitiligo.
56 citations
,
January 2023 in “Genes & Diseases” Repurposing existing drugs and using micronutrients may effectively target cancer stem cells and improve cancer treatment.
18 citations
,
April 2022 in “Frontiers in bioengineering and biotechnology” Gelatin microspheres with stem cells speed up healing in diabetic wounds.
25 citations
,
February 2021 in “Diabetes” Dock5 is important for skin healing and could help treat diabetic wounds.
September 2025 in “Journal of the American Academy of Dermatology” Deuruxolitinib significantly improves hair satisfaction in severe alopecia areata patients.
168 citations
,
December 1986 in “Cancer Chemotherapy and Pharmacology” Epirubicin is as effective as doxorubicin for cancer treatment with less heart damage, but doesn't work on doxorubicin-resistant cancers.
1 citations
,
December 2023 in “Journal of the European Academy of Dermatology and Venereology”
4 citations
,
October 2018 in “Asia-Pacific Journal of Clinical Oncology” CDK4/6 inhibitors have improved treatment outcomes for certain advanced breast cancer patients.
1 citations
,
May 2021 in “Annals of the rheumatic diseases” Tofacitinib is a promising treatment for children with rheumatic diseases.
November 2025 in “SKIN The Journal of Cutaneous Medicine” Upadacitinib effectively treats severe alopecia areata and is safe.
March 2025 in “International Journal of Trichology” Janus kinase inhibitors may effectively treat resistant scalp conditions like folliculitis decalvans and dissecting cellulitis.
February 2023 in “Journal of plant science and phytopathology” Jatropha dioica may have antiviral, antifungal, and other medicinal properties, but more research is needed.
54 citations
,
June 2023 in “International Journal of Molecular Sciences” Myricetin shows promise as an anticancer agent by reducing inflammation and enhancing drug effectiveness.
121 citations
,
April 2008 in “The Journal of Clinical Endocrinology & Metabolism” Insulin sensitizers may slightly reduce hirsutism but are less effective than other treatments.
1 citations
,
October 2025 in “International Journal of Dermatology” Ritlecitinib improves emotional well-being and activity levels in alopecia areata patients.
September 2023 in “Journal of the American Academy of Dermatology” ICI therapy increases the risk of gastrointestinal and endocrine issues in psoriasis patients.
BMD-1141 effectively regrows hair in alopecia areata with less frequent dosing than current treatments.
March 2026 in “The Journal of Dermatology” Ritlecitinib is cost-effective for severe alopecia areata in Japan.
4 citations
,
May 2023 in “Cells” Baricitinib and its combination with lonafarnib improve fat cell formation in certain genetic disorders.
2 citations
,
September 2024 in “PLoS ONE” Bendamustine combined with tucidinostat may effectively treat adult T-cell leukemia.
2 citations
,
May 2025 in “Journal of the European Academy of Dermatology and Venereology” Ritlecitinib improves hair regrowth in alopecia areata over 24 months.
September 2023 in “Journal of the American Academy of Dermatology” Topical tofacitinib helped a man with severe scalp condition after other treatments failed.